S&P 500   3,818.83
DOW   31,029.31
QQQ   283.80
S&P 500   3,818.83
DOW   31,029.31
QQQ   283.80
S&P 500   3,818.83
DOW   31,029.31
QQQ   283.80
S&P 500   3,818.83
DOW   31,029.31
QQQ   283.80

Dynavax Technologies Stock Forecast, Price & News

+0.62 (+5.09%)
(As of 06/29/2022 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
1.42 million shs
Average Volume
2.36 million shs
Market Capitalization
$1.62 billion
P/E Ratio
Dividend Yield
Price Target
30 days | 90 days | 365 days | Advanced Chart

Receive DVAX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Dynavax Technologies and its competitors with MarketBeat's FREE daily newsletter.

DVAX Stock Forecast (MarketRank)

Overall MarketRank

2.30 out of 5 stars

Medical Sector

547th out of 1,432 stocks

Pharmaceutical Preparations Industry

239th out of 685 stocks

Analyst Opinion: 3.3Community Rank: 4.4Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 1.3 5 -4 -3 -2 -1 -
Dynavax Technologies logo

About Dynavax Technologies (NASDAQ:DVAX)

Dynavax Technologies Corporation, a biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. It also manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B. Dynavax Technologies Corporation has a collaboration agreement with Valneva Scotland Limited; agreement with Serum Institute of India Pvt. Ltd.; and sublicense agreement with Merck, Sharp & Dohme Corp. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. Dynavax Technologies Corporation was incorporated in 1996 and is headquartered in Emeryville, California.

DVAX Stock News Headlines

See More Headlines

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Price Target and Rating

Average Stock Price Forecast
High Stock Price Forecast
Low Stock Price Forecast
Forecasted Upside/Downside
Consensus Rating
Moderate Buy
Rating Score (0-4)
Research Coverage
3 Analysts


Net Income
$76.71 million
Pretax Margin


Sales & Book Value

Annual Sales
$439.44 million
Cash Flow
$1.04 per share
Book Value
$1.85 per share


Free Float
Market Cap
$1.62 billion

Social Links

Dynavax Technologies Frequently Asked Questions

Should I buy or sell Dynavax Technologies stock right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Dynavax Technologies in the last year. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" Dynavax Technologies stock.
View analyst ratings for Dynavax Technologies
or view top-rated stocks.

What is Dynavax Technologies' stock price forecast for 2022?

3 brokers have issued 1-year price targets for Dynavax Technologies' stock. Their DVAX stock forecasts range from $19.00 to $28.00. On average, they expect Dynavax Technologies' stock price to reach $23.50 in the next twelve months. This suggests a possible upside of 83.7% from the stock's current price.
View analysts' price targets for Dynavax Technologies
or view top-rated stocks among Wall Street analysts.

How has Dynavax Technologies' stock performed in 2022?

Dynavax Technologies' stock was trading at $14.07 on January 1st, 2022. Since then, DVAX shares have decreased by 9.1% and is now trading at $12.79.
View the best growth stocks for 2022 here

When is Dynavax Technologies' next earnings date?

Dynavax Technologies is scheduled to release its next quarterly earnings announcement on Wednesday, August 3rd 2022.
View our earnings forecast for Dynavax Technologies

How were Dynavax Technologies' earnings last quarter?

Dynavax Technologies Co. (NASDAQ:DVAX) announced its earnings results on Thursday, May, 5th. The biopharmaceutical company reported $0.22 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.24 by $0.02. The biopharmaceutical company earned $113.99 million during the quarter, compared to analysts' expectations of $117.76 million. Dynavax Technologies had a trailing twelve-month return on equity of 87.36% and a net margin of 23.12%. During the same period last year, the firm earned $0.01 EPS.
View Dynavax Technologies' earnings history

Who are Dynavax Technologies' key executives?

Dynavax Technologies' management team includes the following people:

What is Eddie Gray's approval rating as Dynavax Technologies' CEO?

13 employees have rated Dynavax Technologies CEO Eddie Gray on Glassdoor.com. Eddie Gray has an approval rating of 59% among Dynavax Technologies' employees. This puts Eddie Gray in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Dynavax Technologies own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Dynavax Technologies investors own include Puma Biotechnology (PBYI), BioMarin Pharmaceutical (bmrn), (MDVN) (MDVN), Incyte (incy), Sorrento Therapeutics (SRNE), Vaxart (VXRT), Matinas BioPharma (MTNB), First Solar (FSLR), Inovio Pharmaceuticals (INO) and ADMA Biologics (ADMA).

What is Dynavax Technologies' stock symbol?

Dynavax Technologies trades on the NASDAQ under the ticker symbol "DVAX."

How do I buy shares of Dynavax Technologies?

Shares of DVAX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Dynavax Technologies' stock price today?

One share of DVAX stock can currently be purchased for approximately $12.79.

How much money does Dynavax Technologies make?

Dynavax Technologies (NASDAQ:DVAX) has a market capitalization of $1.62 billion and generates $439.44 million in revenue each year. The biopharmaceutical company earns $76.71 million in net income (profit) each year or $0.549990 on an earnings per share basis.

How many employees does Dynavax Technologies have?

Dynavax Technologies employs 311 workers across the globe.

When was Dynavax Technologies founded?

Dynavax Technologies was founded in 1996.

How can I contact Dynavax Technologies?

Dynavax Technologies' mailing address is 2100 Powell Street Suite 900, Emeryville CA, 94608. The official website for Dynavax Technologies is www.dynavax.com. The biopharmaceutical company can be reached via phone at (510) 848-5100, via email at [email protected], or via fax at 510-848-1327.

This page (NASDAQ:DVAX) was last updated on 6/30/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.